Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.53 |
| ▸ | CTSD | P07339 | 16/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637001 | 1.00 | BACE1 (0.53) | BACE1CTSDBACE2CCR1ALDH1A1 | |
| SCHEMBL14602362 | 0.90 | BACE1 (0.43) | BACE1CTSDBACE2CCR1 | |
| SCHEMBL5619035 | 0.80 | REN (0.48) | — | |
| SCHEMBL5619031 | 0.80 | REN (0.48) | — | |
| SCHEMBL5853351 | 0.80 | CTSD (0.54) | BACE1CTSDBACE2 | |
| SCHEMBL5853344 | 0.80 | CTSD (0.54) | BACE1CTSDBACE2 | |
| SCHEMBL8366465 | 0.78 | BACE1 (0.43) | BACE1CTSDBACE2CCR1 | |
| SCHEMBL5620638 | 0.77 | BACE1 (0.48) | BACE1CTSDBACE2 | |
| SCHEMBL5620640 | 0.77 | BACE1 (0.48) | BACE1CTSDBACE2 | |
| SCHEMBL5620238 | 0.77 | BACE1 (0.45) | BACE1CTSDBACE2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | claimed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | claimed |
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 607/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.